These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 33076517

  • 1. Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice.
    Reig-López J, Maldonado MDM, Merino-Sanjuan M, Cruz-Collazo AM, Ruiz-Calderón JF, Mangas-Sanjuán V, Dharmawardhane S, Duconge J.
    Pharmaceutics; 2020 Oct 15; 12(10):. PubMed ID: 33076517
    [Abstract] [Full Text] [Related]

  • 2. Physiologically-based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans.
    Ganti A, Yu S, Sharpnack D, Ingalla E, De Bruyn T.
    Biopharm Drug Dispos; 2023 Aug 15; 44(4):301-314. PubMed ID: 37102506
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer.
    Velázquez-Vega LE, Rivera-Robles M, Sánchez-Álvarez AO, Vivas-Mejía PE, Aponte-Reyes M, Cruz-Collazo AM, Grafals-Ruiz N, Dorta-Estremera S, Hernández-O'Farrill E, Vlaar CP, Dharmawardhane S.
    Transl Oncol; 2024 Jun 15; 44():101928. PubMed ID: 38489873
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167 in Mice by Supercritical Fluid Chromatography-Tandem Mass Spectrometry.
    Maldonado MDM, Rosado-González G, Bloom J, Duconge J, Ruiz-Calderón JF, Hernández-O'Farrill E, Vlaar C, Rodríguez-Orengo JF, Dharmawardhane S.
    ACS Omega; 2019 Nov 05; 4(19):17981-17989. PubMed ID: 31720502
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer.
    Cruz-Collazo A, Ruiz-Calderon JF, Picon H, Borrero-Garcia LD, Lopez I, Castillo-Pichardo L, Del Mar Maldonado M, Duconge J, Medina JI, Bayro MJ, Hernández-O'Farrill E, Vlaar CP, Dharmawardhane S.
    Mol Cancer Ther; 2021 Dec 05; 20(12):2420-2432. PubMed ID: 34607932
    [Abstract] [Full Text] [Related]

  • 6. Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models.
    Torres-Sanchez A, Rivera-Robles M, Castillo-Pichardo L, Martínez-Ferrer M, Dorta-Estremera SM, Dharmawardhane S.
    Front Oncol; 2023 Dec 05; 13():1152458. PubMed ID: 37397366
    [Abstract] [Full Text] [Related]

  • 7. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer.
    Humphries-Bickley T, Castillo-Pichardo L, Hernandez-O'Farrill E, Borrero-Garcia LD, Forestier-Roman I, Gerena Y, Blanco M, Rivera-Robles MJ, Rodriguez-Medina JR, Cubano LA, Vlaar CP, Dharmawardhane S.
    Mol Cancer Ther; 2017 May 05; 16(5):805-818. PubMed ID: 28450422
    [Abstract] [Full Text] [Related]

  • 8. Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of In Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model.
    Chen Y, Zhao K, Liu F, Li Y, Zhong Z, Hong S, Liu X, Liu L.
    Drug Metab Dispos; 2018 Jun 05; 46(6):897-907. PubMed ID: 29618575
    [Abstract] [Full Text] [Related]

  • 9. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
    Loisios-Konstantinidis I, Cristofoletti R, Jamei M, Turner D, Dressman J.
    Pharmaceutics; 2020 Nov 02; 12(11):. PubMed ID: 33147873
    [Abstract] [Full Text] [Related]

  • 10. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.
    Singh AP, Zheng X, Lin-Schmidt X, Chen W, Carpenter TJ, Zong A, Wang W, Heald DL.
    MAbs; 2020 Nov 02; 12(1):1688616. PubMed ID: 31852337
    [Abstract] [Full Text] [Related]

  • 11. Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice.
    Maaß C, Rivas JR, Attarwala AA, Hardiansyah D, Niedermoser S, Litau S, Wängler C, Wängler B, Glatting G.
    Nucl Med Biol; 2016 Apr 02; 43(4):243-6. PubMed ID: 27067044
    [Abstract] [Full Text] [Related]

  • 12. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.
    Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T.
    Cancer Chemother Pharmacol; 2017 Nov 02; 80(5):1013-1026. PubMed ID: 28988277
    [Abstract] [Full Text] [Related]

  • 13. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
    Boger E, Fridén M.
    J Aerosol Med Pulm Drug Deliv; 2019 Feb 02; 32(1):1-12. PubMed ID: 29878860
    [Abstract] [Full Text] [Related]

  • 14. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.
    Chetty M, Li L, Rose R, Machavaram K, Jamei M, Rostami-Hodjegan A, Gardner I.
    Front Immunol; 2014 Feb 02; 5():670. PubMed ID: 25601866
    [Abstract] [Full Text] [Related]

  • 15. Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia.
    Lee J, Kim MG, Jeong HC, Shin KH.
    Transl Clin Pharmacol; 2021 Mar 02; 29(1):33-44. PubMed ID: 33854999
    [Abstract] [Full Text] [Related]

  • 16. Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics.
    Yu Y, DuBois SG, Wetmore C, Khosravan R.
    AAPS J; 2020 Jan 23; 22(2):31. PubMed ID: 31975150
    [Abstract] [Full Text] [Related]

  • 17. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
    Nakamaru Y, Emoto C, Shimizu M, Yamazaki H.
    Biopharm Drug Dispos; 2015 Apr 23; 36(3):148-62. PubMed ID: 25450725
    [Abstract] [Full Text] [Related]

  • 18. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M, Kedderis GL, Yan GZ, Clewell HJ.
    Toxicology; 2015 Jun 05; 332():52-66. PubMed ID: 24863738
    [Abstract] [Full Text] [Related]

  • 19. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS.
    Chem Biol Interact; 2007 Mar 20; 166(1-3):352-9. PubMed ID: 17324392
    [Abstract] [Full Text] [Related]

  • 20. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals.
    Shimizu H, Yoshida K, Nakada T, Kojima K, Ogasawara A, Nakamaru Y, Yamazaki H.
    Drug Metab Dispos; 2019 Feb 20; 47(2):114-123. PubMed ID: 30420404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.